Relationship between SARS-CoV-2 infection and the incidence of ventilator-associated lower respiratory tract infections: a European multicenter cohort study.
COVID-19
Critical illness
SARS-CoV-2
Ventilator-associated pneumonia
Ventilator-associated tracheobronchitis
Journal
Intensive care medicine
ISSN: 1432-1238
Titre abrégé: Intensive Care Med
Pays: United States
ID NLM: 7704851
Informations de publication
Date de publication:
02 2021
02 2021
Historique:
received:
13
08
2020
accepted:
11
11
2020
pubmed:
4
1
2021
medline:
26
2
2021
entrez:
3
1
2021
Statut:
ppublish
Résumé
Although patients with SARS-CoV-2 infection have several risk factors for ventilator-associated lower respiratory tract infections (VA-LRTI), the reported incidence of hospital-acquired infections is low. We aimed to determine the relationship between SARS-CoV-2 pneumonia, as compared to influenza pneumonia or no viral infection, and the incidence of VA-LRTI. Multicenter retrospective European cohort performed in 36 ICUs. All adult patients receiving invasive mechanical ventilation > 48 h were eligible if they had: SARS-CoV-2 pneumonia, influenza pneumonia, or no viral infection at ICU admission. VA-LRTI, including ventilator-associated tracheobronchitis (VAT) and ventilator-associated pneumonia (VAP), were diagnosed using clinical, radiological and quantitative microbiological criteria. All VA-LRTI were prospectively identified, and chest-X rays were analyzed by at least two physicians. Cumulative incidence of first episodes of VA-LRTI was estimated using the Kalbfleisch and Prentice method, and compared using Fine-and Gray models. 1576 patients were included (568 in SARS-CoV-2, 482 in influenza, and 526 in no viral infection groups). VA-LRTI incidence was significantly higher in SARS-CoV-2 patients (287, 50.5%), as compared to influenza patients (146, 30.3%, adjusted sub hazard ratio (sHR) 1.60 (95% confidence interval (CI) 1.26 to 2.04)) or patients with no viral infection (133, 25.3%, adjusted sHR 1.7 (95% CI 1.2 to 2.39)). Gram-negative bacilli were responsible for a large proportion (82% to 89.7%) of VA-LRTI, mainly Pseudomonas aeruginosa, Enterobacter spp., and Klebsiella spp. The incidence of VA-LRTI is significantly higher in patients with SARS-CoV-2 infection, as compared to patients with influenza pneumonia, or no viral infection after statistical adjustment, but residual confounding may still play a role in the effect estimates.
Identifiants
pubmed: 33388794
doi: 10.1007/s00134-020-06323-9
pii: 10.1007/s00134-020-06323-9
pmc: PMC7778569
doi:
Types de publication
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
188-198Subventions
Organisme : French Government « Programme Investissement d'Avenir » (I-SITE ULNE) managed by the Agence Nationale de la Recherche
ID : coVAPid project
Investigateurs
Raphaël Favory
(R)
Sébastien Preau
(S)
Mercé Jourdain
(M)
Julien Poissy
(J)
Chaouki Bouras
(C)
Piehr Saint Leger
(P)
Hanane Fodil
(H)
François Aptel
(F)
Thierry Van Der Linden
(T)
Arnaud W Thille
(AW)
Elie Azoulay
(E)
Frédéric Pène
(F)
Keyvan Razazi
(K)
François Bagate
(F)
Damien Contou
(D)
Guillaume Voiriot
(G)
Didier Thevenin
(D)
Bertrand Guidet
(B)
Loïc Le Guennec
(L)
Achille Kouatchet
(A)
Stephan Ehrmann
(S)
Guillaume Brunin
(G)
Elise Morawiec
(E)
Alexandre Boyer
(A)
Laurent Argaud
(L)
Sebastian Voicu
(S)
Ania Nieszkowska
(A)
Benjamin Kowalski
(B)
Gemma Goma
(G)
Emilio Diaz
(E)
Luis Morales
(L)
Vassiliki Tsolaki
(V)
George Gtavriilidis
(G)
Spyros D Mentzelopoulos
(SD)
David Nora
(D)
Sean Boyd
(S)
Luis Coelho
(L)
Julien Maizel
(J)
Damien Du Cheyron
(D)
Mehdi Imouloudene
(M)
Jean-Pierre Quenot
(JP)
Arnaud Guilbert
(A)
Catia Cilloniz
(C)
Commentaires et corrections
Type : ErratumIn
Références
N Engl J Med. 2020 Jul 9;383(2):120-128
pubmed: 32437596
JAMA Intern Med. 2020 Sep 1;180(9):1152-1154
pubmed: 32602883
Clin Microbiol Infect. 2012 Mar;18(3):268-81
pubmed: 21793988
Intensive Care Med. 2020 May;46(5):888-906
pubmed: 32157357
Front Immunol. 2018 Jun 22;9:1421
pubmed: 29988424
Am J Respir Crit Care Med. 2002 Apr 1;165(7):867-903
pubmed: 11934711
JAMA. 2013 Oct 16;310(15):1571-80
pubmed: 24097234
Antimicrob Agents Chemother. 2010 Nov;54(11):4851-63
pubmed: 20733044
Crit Care. 2012 Dec 12;16(2):R65
pubmed: 22524447
Intensive Care Med. 2015 Jan;41(1):34-48
pubmed: 25427866
Lancet Respir Med. 2020 Dec;8(12):1201-1208
pubmed: 32861276
Crit Care. 2020 Jun 12;24(1):338
pubmed: 32532324
Stat Med. 2002 Nov 30;21(22):3317-24
pubmed: 12407674
BMJ. 2020 May 22;369:m1923
pubmed: 32444358
Intensive Care Med. 2020 Sep;46(9):1727-1731
pubmed: 32648089
Gastroenterology. 2020 Sep;159(3):944-955.e8
pubmed: 32442562
Clin Infect Dis. 2020 Dec 17;71(10):2669-2678
pubmed: 32497191
JAMA Intern Med. 2020 Jul 1;180(7):934-943
pubmed: 32167524
Intensive Care Med. 2020 Jun;46(6):1124-1126
pubmed: 32328726
Clin Infect Dis. 2004 Aug 15;39(4):511-6
pubmed: 15356814
Biometrics. 1978 Dec;34(4):541-54
pubmed: 373811
Lancet Respir Med. 2020 May;8(5):475-481
pubmed: 32105632
Cytokine. 2020 Sep;133:155151
pubmed: 32544563
BMJ. 2020 May 29;369:m1996
pubmed: 32471884
BMJ. 2020 May 22;369:m1985
pubmed: 32444460
Intensive Care Med. 2020 Sep;46(9):1769-1771
pubmed: 32514592
Lancet Respir Med. 2015 Nov;3(11):859-68
pubmed: 26472037